|1.||Hauber, Joachim: 5 articles (07/2015 - 01/2012)|
|2.||Pällmann, Nora: 3 articles (07/2015 - 01/2012)|
|3.||Balabanov, Stefan: 3 articles (07/2015 - 01/2012)|
|4.||Preukschas, Michael: 3 articles (07/2015 - 01/2012)|
|5.||Sievert, Henning: 3 articles (07/2015 - 01/2012)|
|6.||Braig, Melanie: 3 articles (07/2015 - 01/2012)|
|7.||Bokemeyer, Carsten: 3 articles (07/2015 - 01/2012)|
|8.||Maier, Bernhard: 3 articles (03/2014 - 06/2010)|
|9.||Tersey, Sarah A: 3 articles (03/2014 - 06/2010)|
|10.||Mirmira, Raghavendra G: 3 articles (03/2014 - 06/2010)|
08/02/1996 - "Since our studies demonstrated that GC7 mimics the action of DFMO on tumor differentiation, it is likely that the effect of DFMO on tumor differentiation is mediated by hypusine formation and that GC7 represents a more specific inhibitor that can alter the differentiation program in certain tumor cells."
01/15/2014 - "We found that proliferation of cervical cancer cells can be blocked by DOHH inhibition with either of these pharmacologic agents, as well as by RNA interference-mediated silencing of eIF5A, DOHH, or another enzyme in the hypusine pathway. "
07/01/2012 - "eIF5A is regulated by post-translational hypusine modification, and overexpression of hypusination-resistant mutants of eIF5A induces apoptosis in many types of cancer cells. "
07/24/2015 - "Moreover, these findings highlight functional diversity of the hypusine system compared with lower eukaryotes and indicate eIF-5A2 as a valuable and safe target for therapeutic intervention in cancer. "
01/01/2012 - "Recent work demonstrated that the posttranslational hypusine modification of the eukaryotic initiation factor 5A (eIF-5A) is a crucial regulator of cell proliferation, differentiation and an important factor in tumor formation, progression and maintenance. "
07/01/2010 - "Because the hypusine modification is absolutely required for eIF5A action in cytokine signaling, we propose that this modification could serve as a new drug target for islet beta cell protection in the setting of diabetic inflammation."
07/01/2010 - "Hypusine: a new target for therapeutic intervention in diabetic inflammation."
06/01/2010 - "The unique hypusine modification of eIF5A promotes islet beta cell inflammation and dysfunction in mice."
03/01/2014 - "Recent studies have shown that polyamines, which are essential for mRNA translation, cellular replication, and the formation of the hypusine modification of eIF5A may play an important role in the progression of cellular inflammation. "
07/24/2015 - "Hypusine modification of the eukaryotic initiation factor 5A (eIF-5A) is emerging as a crucial regulator in cancer, infections, and inflammation. "
08/19/1988 - "Isolation and characterization of an 18 kDa hypusine-containing protein from cultured NB-15 mouse neuroblastoma cells."
03/14/1988 - "NAD+ stimulated the spermidine-dependent hypusine formation on the 18 kDa protein in cytosolic lysates derived from NB-15 mouse neuroblastoma cells."
03/14/1988 - "When incubated with cultured mouse neuroblastoma cells under growth stimulatory condition, [3H]putrescine or [3H]spermidine can metabolically label a cellular protein of apparent molecular mass 18 kDa. The labeling, which leads to hypusine formation, is due to a covalent linkage between a lysine residue and the butylamino group derived from spermidine. "
06/01/2010 - "A role for the hypusine residue of eIF5A in islet inflammatory responses was suggested by the observation that inhibition of hypusine synthesis reduced translation of iNOS-encoding mRNA in rodent beta cells and human islets and protected mice against the development of glucose intolerance the low-dose streptozotocin model of diabetes. "
|3.||eukaryotic translation initiation factor 5A
|4.||Peptide Initiation Factors (Initiation Factor)
|7.||Epidermal Growth Factor (EGF)
|8.||Complementary DNA (cDNA)
|9.||Interferon-alpha (Interferon Alfa)